These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 12775571)

  • 1. A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy.
    Stoll BR; Migliorini C; Kadambi A; Munn LL; Jain RK
    Blood; 2003 Oct; 102(7):2555-61. PubMed ID: 12775571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Circulating endothelial cells: biomarkers for monitoring activity of antiangiogenic therapy].
    Farace F; Bidart JM
    Bull Cancer; 2007 Jul; 94 Spec No():S254-9. PubMed ID: 17846012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating endothelial cells as a novel marker of angiogenesis.
    Mancuso P; Calleri A; Cassi C; Gobbi A; Capillo M; Pruneri G; Martinelli G; Bertolini F
    Adv Exp Med Biol; 2003; 522():83-97. PubMed ID: 12674213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis.
    Gately S; Kerbel R
    Prog Exp Tumor Res; 2003; 37():179-92. PubMed ID: 12795055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. III. Angiogenesis: complexity of tumor vasculature and microenvironment.
    Furuya M; Yonemitsu Y; Aoki I
    Curr Pharm Des; 2009; 15(16):1854-67. PubMed ID: 19519428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy and the tumor microenvironment: the contribution of circulating endothelial cells.
    Bertolini F
    Cancer Metastasis Rev; 2008 Mar; 27(1):95-101. PubMed ID: 18066648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New approach to modeling of antiangiogenic treatment on the basis of Hahnfeldt et al. model.
    Poleszczuk J; Bodnar M; Foryś U
    Math Biosci Eng; 2011 Apr; 8(2):591-603. PubMed ID: 21631148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
    Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
    Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
    Drevs J; Fakler J; Eisele S; Medinger M; Bing G; Esser N; Marmé D; Unger C
    Anticancer Res; 2004; 24(3a):1759-63. PubMed ID: 15274352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical modelling of flow through vascular networks: implications for tumour-induced angiogenesis and chemotherapy strategies.
    McDougall SR; Anderson AR; Chaplain MA; Sherratt JA
    Bull Math Biol; 2002 Jul; 64(4):673-702. PubMed ID: 12216417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Angiogenesis and endothelial cells in blood neoplasms].
    Usnarska-Zubkiewicz L; Poreba M; Kuliczkowski K
    Przegl Lek; 2006; 63(3):146-50. PubMed ID: 16969900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiogenesis in hematologic malignancies.
    Moehler TM; Neben K; Ho AD; Goldschmidt H
    Ann Hematol; 2001 Dec; 80(12):695-705. PubMed ID: 11797109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis as a target for tumor treatment.
    Gastl G; Hermann T; Steurer M; Zmija J; Gunsilius E; Unger C; Kraft A
    Oncology; 1997; 54(3):177-84. PubMed ID: 9143396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor vasculature targeted therapies: getting the players organized.
    Molema G; Meijer DK; de Leij LF
    Biochem Pharmacol; 1998 Jun; 55(12):1939-45. PubMed ID: 9714313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelial Side Population Cells Contribute to Tumor Angiogenesis and Antiangiogenic Drug Resistance.
    Naito H; Wakabayashi T; Kidoya H; Muramatsu F; Takara K; Eino D; Yamane K; Iba T; Takakura N
    Cancer Res; 2016 Jun; 76(11):3200-10. PubMed ID: 27197162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
    Shaked Y; Ciarrocchi A; Franco M; Lee CR; Man S; Cheung AM; Hicklin DJ; Chaplin D; Foster FS; Benezra R; Kerbel RS
    Science; 2006 Sep; 313(5794):1785-7. PubMed ID: 16990548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.